

CardieX & Invariant enable clinical trials with advanced new AI medical technology

05 January 2023 | News

CardieX and Invariant will work cohesively to conduct trials and improve patient outcomes

Australia's CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes, has announced a partnership between its ATCOR subsidiary and Invariant, a US-based data-driven health technology company that empowers individuals with precision artificial intelligence (AI) to improve quality, equity and safety, and provides comprehensive, integrated, high quality data to accelerate research and innovation.

The new partnership will allow ATCOR and Invariant to jointly conduct clinical trials and research on maternal health and cardiovascular disease.

In an effort to improve patient outcomes across clinical trials and healthcare research, the partnership will primarily focus on the integration of digital vascular biomarkers using ATCOR's SphygmoCor technology into Invariant's health platform, thereby enabling a more patient-focused monitoring of hypertensive disorders that signal risk factors across multiple therapeutic areas (including maternal health and cardiovascular diseases).

Together, ATCOR and Invariant are redefining patient-centric monitoring by integrating a collection of digital vascular biomarkers which will seamlessly correlate with imaging and molecular biomarkers in order to better understand and personalise a patient's vascular health.

The "Pulse", a new device from CardieX subsidiary CONNEQT, will provide advanced arterial health metrics to users from the comfort of their own home. Pulse was developed as a primary decentralized clinical trial device to enhance patient monitoring. Pulse will integrate with Invariant's health platform for a holistic perspective of patient care with EMR data, imaging data, molecular data, and other relevant clinical data.